Verition Fund Management
AVDL

Verition Fund Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Verition Fund Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-450,981
Closed -$9.72M – 2326
2025
Q4 		$9.72M Buy
+450,981
New +$8.76M 0.04% 478
2025
Q3 		– Sell
-13,010
Closed -$115K – 3754
2025
Q2 		$115K Sell
13,010
-20,395
-61% -$179K ﹤0.01% 3467
2025
Q1 		$262K Buy
33,405
+15,860
+90% +$133K ﹤0.01% 2926
2024
Q4 		$184K Sell
17,545
-2,405
-12% -$29.2K ﹤0.01% 2997
2024
Q3 		$262K Buy
+19,950
New +$304K ﹤0.01% 2724

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Verition Fund Management's AVDL Position: Q1 2026 in Review

Verition Fund Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 450,981 shares — an estimated $9.72M sold.

Verition Fund Management first reported a position in AVDL in Q3 2024 and held it in 5 quarters. The position peaked at $9.72M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Verition Fund Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 450,981 Avadel Pharmaceuticals shares in Q1 2026, an estimated $9.72M.
  • Verition Fund Management first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Verition Fund Management's Avadel Pharmaceuticals position peaked at $9.72M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.